XENE

XENON PHARMACEUTICALS INC

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary

XENON PHARMACEUTICALS INC (XENE) is held as common stock by 7 tracked hedge-fund managers, with a combined reported value of ~$196.15M; the largest are Ken Griffin, Paul Tudor Jones, Izzy Englander. 1 tracked manager also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 2 added, 2 trimmed. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.

Attention · MediumThis quarter · Mixed

Common-stock holders71 also report options

Congress trades0

Price$36.72vs quarter-end-39.17%

Sectors0

This quarter's moves

New1

Added2

Trimmed / sold2

Top holder

Ken Griffin

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

Baker Bros. AdvisorsHold

Value $22.35M0.1% of portfolio370,2082026 Q2

Stanley DruckenmillerHold

Value $14.40M0.3% of portfolio238,6002026 Q2

Investor	Period	Value	Shares	% of portfolio	Action
Baker Bros. Advisors	2026 Q2	$22.35M	370,208	0.1%	Hold
Stanley Druckenmiller	2026 Q2	$14.40M	238,600	0.3%	Hold

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Ken GriffinCALL—

Value $2.32M— of portfolio38,4002026 Q2

Ken GriffinPUT—

Value $513.1K— of portfolio8,5002026 Q2

Investor	Period	Value	Shares	% of portfolio	Action
Ken GriffinCALL	2026 Q2	$2.32M	38,400	—	—
Ken GriffinPUT	2026 Q2	$513.1K	8,500	—	—

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.